Sirolimus in solid organ transplantation: Current therapies and new frontiers

Immunotherapy

Volumn 3, Issue 12, 2011, Pages 1487-1497

  Veroux, Massimiliano ^a   Tallarita, Tiziano ^a,b   Corona, Daniela ^a   D'Assoro, Antonino ^b   Gurrieri, Carmelina ^a   Veroux, Pierfrancesco ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b MAYO CLINIC   (United States)

Author keywords

cancer; heart transplantation; kidney transplantation; lung transplantation; lymphocele; pediatric transplantation; pneumonitis; proteinuria; sirolimus; transplantation

Indexed keywords

BASILIXIMAB; CALCINEURIN INHIBITOR; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID;

ACUTE GRAFT REJECTION; BONE MARROW SUPPRESSION; DELAYED GRAFT FUNCTION; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; EDEMA; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMAN; HYPERLIPIDEMIA; KIDNEY PANCREAS TRANSPLANTATION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LYMPHOCELE; MONOTHERAPY; MOUTH ULCER; NEPHROTOXICITY; ORGAN TRANSPLANTATION; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; REVIEW; SOLID ORGAN TRANSPLANTATION; WOUND HEALING IMPAIRMENT;

CELL CYCLE; GRAFT REJECTION; HUMANS; HYPERLIPIDEMIAS; IMMUNOSUPPRESSION; ORGAN TRANSPLANTATION; SIROLIMUS; WOUND HEALING;

EID: 81855173480     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.11.143     Document Type: Review

References (96)

1. Gupta P, Kaufman S, Fishbein TM. Sirolimus for solid organ transplantation in children. Pediatr. Transplant. 9(3), 269-276 (2005).
2. Sehgal SN. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant. Proc. 35(3 Suppl.), 7S-14S (2003).
3. Neuhaus P, Klupp J, Langrehr JM. mTOR inhibitors: an overview. Liver Transpl. 7(6), 473-484 (2001).
4. Zimmerman JJ, Harper D, Getsy J, Jusko WJ. Pharmacokinetic interactions between sirolimus and microemulsion cyclosporine when orally administered jointly and 4 hours apart in healthy volunteers. J. Clin. Pharmacol. 43(10), 1168-1176 (2003).
5. Bai S, Stepkowski SM, Kahan BD, Brunner LJ. Metabolic interaction between cyclosporine and sirolimus. Transplantation 77(10), 1507-1512 (2004).
6. McAlister VC, Mahalati K, Peltekian KM, Fraser A, MacDonald AS. A clinical pharmacokinetic study of tacrolimus and sirolimus combination immunosuppression comparing simultaneous to separated administration. Ther. Drug Monit. 24(3), 346-350 (2002).
7. Rowshani AT, Scholten EM, Bemelman F et al. No difference in degree of interstitial Sirius red-stained area in serial biopsies from area under concentration-over-time curves-guided cyclosporine versus tacrolimus-treated renal transplant recipients at one year. J. Am. Soc. Nephrol. 17(1), 305-312 (2006).
8. Flechner SM. Sirolimus in kidney transplantation. Indications and practical guidelines: de novo sirolimus-based therapy without calcineurin inhibitors. Transplantation 87(Suppl. 8), S1-S6 (2009).
9. Flechner SM, Kurian SM, Solez K et al. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am. J. Transplant. 4(11), 1776-1785 (2004).
10. Flechner SM, Goldfarb D, Solez K et al. Kidney transplantation with sirolimus and MMF based immunosuppression: 5 year results of a randomized prospective trial compared with calcineurin inhibitor drugs. Transplantation 83 (7), 883-892 (2007).
11. Lo A, Egidi MF, Gaber LW et al. Comparison of sirolimus-based calcineurin inhibitor-sparing and calcineurin inhibitor-free regimens in cadaveric renal transplantation. Transplantation 77(8), 1228-1235 (2004).
12. Lebranchu Y, Thierry A, Thervet E et al. Efficacy and safety of early cyclosporine conversion to sirolimus with continued MMF. Four year results of the Postconcept study. Am. J. Transplant. 11(8), 1665-1675 (2011).
13. Weir MR, Mulgaonkar S, Chan L et al. Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial. Kidney Int. 79(8), 897-907 (2011).
14. Knight RJ, Podder H, Kerman RH et al. Comparing an early corticosteroid/late calcineurin-free immunosuppression protocol to a sirolimus-, cyclosporine A-, and prednisone-based regimen for pancreas- kidney transplantation. Transplantation 89(6), 727-732 (2010).
15. Glotz D, Charpentier B, Abramovicz D et al. Thymoglobulin induction and sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids. Transplantation 89(12), 1511-1517 (2010).
16. Ekberg H, Tedesco-Silva H, Demirbas A et al. Reduced exposure to calcineurin inhibitors in renal tranpslantation. N. Engl. J. Med. 357 (25), 2562-2575 (2007)
17. Flechner SM, Glyda M, Cockfield S et al. The ORION study: comparison of two sirolimu-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. Am. J. Transplant. 11(8), 1633-1644 (2011).
18. Tsai MK, Wu FL, Lai IR, Lee CY, Hu RH, Lee PH. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy. Int. J. Artif. Organs 32(6), 371-380 (2009).
19. Kahan BD, Benavides C, Schoenberg L, Podbielski J, Green C. Addition of induction therapy offsets the hazard of marked calcineurin minimization among renal transplant recipients treated with sirolimus. Clin. Nephrol. 73(5), 344-353 (2010).
20. Gonwa T, Mendez R, Yang HC, Weinstein S, Jensik S, Steinberg S. Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months. Transplantation 75(8), 1213-1220 (2003).
21. Mendez R, Gonwa T, Yang HC, Weinstein S, Jensik S, Steinberg S. A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1 year. Transplantation 80(3), 303-309 (2005).
22. Ciancio G, Burke GW, Gaynor JJ et al. A randomized long-term trial of tacrolimus/ sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/ sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year. Transplantation 77(2), 252-258 (2004).
23. Meier-Kriesche HU, Schold JD, Srinivas TR, Howard RJ, Fujita S, Kaplan B. Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared with mycophenolate mofetil combined with tacrolimus. Am. J. Transplant. 5(9), 2273-2280 (2005).
24. Webster AC, Lee VW, Chapman JR, Craig JC. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation 81(9), 1234-1248 (2006).
25. Lebranchu Y, Thierry A, Toupance O et al. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study. Am. J. Transplant. 9(5), 1115-1123 (2009).
26. Guba M, Praschke J, Hugo C et al. Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: one-year analysis of a randomized multicenter trial. Transplantation 90(2), 175-183 (2010).
27. Buchler M, Caillard S, Barbier S et al. Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6 month course of steroids. Am. J. Transplant. 7(11), 2522-2531 (2007).
28. Sellarés J, Moreso F, Ruiz JC, Seron D. Mean glomerular volume after renal transplantation in patients receiving sirolimus and cyclosporine A compared with elimination of cyclosporine A at 3 months. Transplantation 91(1), E5-E6 (2011).
29. Opelz G, Dohler B. Effect on kidney graft survival of reducing or discontinuing maintenance immunosuppression after the first year posttransplant. Transplantation 86(3), 371-376 (2008).
30. Schena FP, Pascoe MD, Alberu J et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24 month efficacy and safety results from the CONVERT trial. Transplantation 87(2), 233-242 (2009).
31. Flechner SM, Friend PJ, Brockmann J et al. Alemtuzumab induction and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free kidney transplant immunosuppression. Am. J. Transplant. 5(12), 3009-3014 (2005).
32. Mahalati K, Kahan BD. A pilot study of steroid withdrawal from kidney transplant recipients on sirolimus-cyclosporine A combination therapy. Transplant. Proc. 33(7-8), 3232-3233 (2001).
33. Woodle ES, Vincenti F, Lorber MI et al. A multicenter pilot study of early (4 day) steroid cessation in renal transplant recipients under simulect, tacrolimus and sirolimus. Am. J. Transplant. 5(1), 157-166 (2005).
34. Hricik DE, Knauss TC, Bodziak KA et al. Withdrawal of steroid therapy in African American kidney transplant recipients receiving sirolimus and tacrolimus. Transplantation 76(6), 938-942 (2003).
35. de Sandes Freitas TV, Harada KM, Felipe CR et al. Steroid or tacrolimus withdrawal in renal transplant recipients using sirolimus. Int. Urol. Nephrol. doi:10.1007/s11255-011-0001-3 (2011) (Epub ahead of print).
36. Vincenti F, Stock P. De novo use of sirolimus in immunosuppression regimens in kidney and kidney-pancreas transplantation at the University of California, San Francisco. Transplant. Proc. 35(Suppl. 3), S183-S186 (2003).
37. Laham G, Sleiman S, Soler Pujol G, Diaz C, Davalos M, Vilches A. Conversion to sirolimus allows preservation of renal function in kidney and kidney-pancreas allograft recipients. Transplant. Proc. 42(1), 309-313 (2010).
38. Rogers J, Ashcraft EE, Emovon OE et al. Long-term outcome of sirolimus rescue in kidney-pancreas transplantation. Transplantation 78(4), 619-622 (2004).
39. Knight RJ, Podder H, Kerman RH et al. Comparing an early corticosteroid/late calcineurin-free immunosuppression protocol to a sirolimus-, cyclosporine A-, and prednisone-based regimen for pancreas-kidney transplantation. Transplantation 89(6), 727-732 (2010).
40. Wiesner RH, Kintmalm G, McDiamid SV et al., Rapamune Liver Transplant Study Group. Sirolimus immunotherapy results in reduced rates of acute rejection in de novo orthotopic liver transplant recipients. Am. J. Transplant. 2(Suppl. 3), 464 (2002).
41. Massoud O, Wiesner RH. The use of sirolimus should be restricted in liver transplantation. J. Hepatol. doi:10.1016/j.jhep.2011.06.012 (2011) (Epub ahead of print
42. Toso C, Merani S, Bigam DL et al. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology 51(4), 1237-1243 (2010).
43. Zimmerman MA, Trotter JF, Wachs M et al. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Liver Transpl. 14(5), 633-638 (2008).
44. Martinez JM, Pulido LB, Bellido CB et al. Rescue immunosuppression with mammalian target of rapamycin inhibitor drugs in liver transplantation. Transplant. Proc. 42(2), 641-643 (2010).
45. Rogers CC, Johnson SR, Mandelbrot DA et al. Timing of sirolimus conversion influences recovery of renal function in liver transplant recipients. Clin. Transplant. 23(6), 887-896 (2009).
46. Harper SJ, Gelson W, Harper IG, Alexander GJ, Gibbs P. Switching to sirolimus-based immunosuppression after liver transplantation is safe and effective: a single, center experience. Transplantation 91(1), 128-132 (2011).
47. Asrani SK, Leise MD, West CP et al. Use of sirolimus in liver transplant recipients with renal insufficiency: a systematic review and meta-analysis. Hepatology 52(4), 1360-1370 (2010).
48. Di Benedetto F, Di Sandro S, De Ruvo N et al. First report on a series of HIV patients undergoing rapamycin monotherapy after liver transplantation. Transplantation 89(6), 733-738 (2010).
49. Mancini D, Pinney S, Burkhoff D et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 108 (1), 48-53 (2003).
50. Keogh A, Richardson M, Ruygrok P et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years. A randomized clinical trial. Circulation 110(17), 2694-2700 (2004).
51. Raiclin E Prasad A, Kremers WK et al. Sirolimus as primary immunosuppression is associated with improved coronary vasomotor function compared with calcineurin inhibitors in stable heart transplant recipients. Eur. Heart J. 30(11), 1356-1363 (2009).
52. Raichlin E, Bae JH, Khalpey Z et al. Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation. Circulation 116(23), 2726-2733 (2007).
53. Delgado JF, Crespo MG, Manito N et al. Usefulness of sirolimus as rescue therapy in heart transplant recipients with renal failure: analysis of the Spanish multicenter observational study (RAPACOR). Transplant. Proc. 41(9), 3835-3837 (2009).
54. Kobashigawa JA, Miller LW, Russel SD et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs cyclosporine with MMF in cardiac transplant patients: 1 year report. Am. J. Transplant. 6(6), 1377-1386 (2006).
55. Khandhar SJ, Shah HV, Shullo MA et al. Long-term effects on renal function of dose-reduced calcineurin inhibitor and sirolimus in cardiac transplant patients. Clin. Transplant. doi:10.1111/j.1399- 0012.2011.01407.x (2011) (Epub ahead of print).
56. Gonzalez-Vilchez F, De Prada JA, Castrillo C, Canteli A, Llano MF, Martin Duran R. Predictors of long-term renal function after conversion to proliferation signal inhibitors in long-term heart transplant recipients. J. Heart Lung Transplant. 30(5), 552-557 (2011).
57. Villanueva J, Boukhamseen A, Bhorade SM. Successful use in lung transplantation of an immunosuppressive regimen aimed at reducing target blood levels of sirolimus and tacrolimus. J. Heart Lung Transplant. 24(4), 421-425 (2005).
58. Vilalta R, Vila A, Nieto J, Callis L. Rapamycin use and rapid withdrawal of calcineurin inhibitors in pediatric renal transplantation. Transplant. Proc. 35(2), 703-704 (2003).
59. Hocker B, Tonshoff B. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option? Paediatr. Drugs 13(1), 49-69 (2011).
60. Blydt-Hansen TD, Gibson IW, Birk PE. Histological progression of chronic renal allograft injury comparing sirolimus and mycophenolate mofetil-based protocols. A single-center, prospective, randomized, controlled study. Pediatr. Transplant. 14(7), 909-918 (2010).
61. Gibelli NE, Tannuri U, Pinho-Apezzato ML et al. Sirolimus in pediatric liver transplantation: a single-center experience. Transplant. Proc. 41(3), 901-903 (2009).
62. Andres AM, Lopez Santamaria M, Ramos E et al. The use of sirolimus as a rescue therapy in pediatric intestinal transplant recipients. Pediatr. Transplant. 14(7), 931-935 (2010).
63. McDonald RA, Smith JM, Ho M et al. Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids. Am. J. Transplant. Proc. 8(5), 984-989 (2008).
64. Benfield MR, Bartosh S, Ikle D et al. A randomized double-blind, placebo controlled trial of steroid withdrawal after pediatric renal transplantation. Am. J. Transplant. 10(1), 81-88 (2010).
65. Campistol JM. Minimizing the risk of posttransplant malignancy. Transplantation 87(Suppl. 8), S19-S22 (2009).
66. Stallone G, Schena A, Infante B et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N. Engl. J. Med. 352(13), 1317-1323 (2005).
67. Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 80(7), 883-889 (2005).
68. Campistol JM, Eris J, Oberbauer R et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J. Am. Soc. Nephrol. 17(2), 581-589 (2006).
69. Kasiske BL, de Mattos A, Flechner SM et al. Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients. Am. J. Transplant. 8(7), 1384-1392 (2008).
70. Elloso MM, Azrolan N, Sehgal SN et al. Protective effect of the immunosuppressant sirolimus against aortic atherosclerosis in apo E-deficient mice. Am. J. Transplant. 3(5), 562-569 (2003).
71. Ikonen TS, Gummert JF, Serkova N et al. Efficacies of sirolimus (rapamycin) and cyclosporine in allograft vascular disease in non-human primates: trough levels of sirolimus correlate with inhibition of progression of arterial intimal thickening. Transpl. Int. 13(Suppl. 1), S314-S320 (2000).
72. Stallone G, Infante B, Grandaliano G, Gesualdo L. Management of side effects of sirolimus therapy. Transplantation 87(Suppl. 8), S23-S26 (2009).
73. Blum CB. Effects of sirolimus on lipids in renal allograft recipients: an analysis using the Framingham risk model. Am. J. Transplant. 2(6), 551-559 (2002).
74. Hong JC, Kahan BD. Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: risk factors, incidence, progression, and management. Transplantation 69(10), 2085-2090 (2000).
75. Augustine JJ, Knauss TC, Schulak JA, Bodziak KA, Siegel C, Hricik DE. Comparative effects of sirolimus and mycophenolate mofetil on erythropoiesis in kidney transplant patients. Am. J. Transplant. 4(12), 2001-2006 (2004).
76. Stallone G, Di Paolo S, Schena A et al. The addition of syrolimus to cyclosporine delays the recovery from delayed graft function but does not affect 1 year graft function. J. Am. Soc. Nephrol. 15(1), 228-233 (2004).
77. Stallone G, Infante B, Pontrelli P et al. Sirolimus and proteinuria in renal transplant patients: evidence for a dose-dependent effect on slit diaphragm-associated proteins. Transplantation 91(9), 997-1004 (2011).
78. Saurina A, Campistol JM, Piera C et al. Conversion from calcineurin inhibitors to sirolimus in chronic allograft dysfunction: changes in glomerular haemodynamics and proteinuria. Nephrol. Dial. Transplant. 21(2), 488-493 (2006).
79. Diekmann F, Budde K, Oppenheimer F, Fritsche L, Neumayer HH, Campistol JM. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am. J. Transplant. 4(11), 1869-1875 (2004).
80. Flechner SM, Zhou L, Derweesh I et al. The impact of sirolimus, mycophenolate mofetil, cyclosporine, azathioprine, and steroids on wound healing in 513 kidney-transplant recipients. Transplantation 76(12), 1729-1734 (2003).
81. Huber S, Bruns CJ, Schmid G et al. Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis. Kidney Int. 71(8), 771-777 (2007).
82. Campistol JM, de Fijter JW, Flechner SM, Langone A, Morelon E, Stckfleth E. mTOR inhibitor-associated dermatologic and mucosal problems. Clin. Transplant. 24(2), 149-156 (2010).
83. Chuang P, Langone AJ. Clobetasol ameliorates aphthous ulceration in renal transplant patients on sirolimus. Am. J. Transplant. 7(3), 714-717 (2008).
84. Johnston O, Rose CL, Webster AC, Gill JS. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J. Am. Soc. Nephrol. 19 (7), 1411-1418 (2008).
85. Teutonico A, Schena PF, Di Paolo S. Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J. Am. Soc. Nephrol. 16(10), 3128-3135 (2005).
86. Veroux M, Corona D, Giuffrida G et al. New-onset diabetes mellitus after kidney transplantation: the role of immunosuppression. Transplant. Proc. 40(6), 1885-1887 (2008).
87. Araki M, Flechner SM, Ismail HR et al. Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitors drugs. Am. J. Transplant. 81(3), 335-341 (2006).
88. Veroux M, Corona D, Veroux P. Kidney transplantation: future challenges. Minerva Chir. 64(1), 75-100 (2009).
89. Veroux M, Corona D, Giuffrida G et al. Sirolimus-based immunosuppression in kidney transplantation for Type 2 diabetic nephropathy. Urol. Int. 84(3), 301-304 (2010).
90. Montalbano M, Neff GW, Yamashiki N et al. A retrospective review of liver transplant patients treated with sirolimus from a single center: an analysis of sirolimus-related complications. Transplantation 78(2), 264-268 (2004).
91. Pham PT, Pham PC, Danovitch GM et al. Sirolimus-associated pulmonary toxicity. Transplantation 77(8), 1215-1220 (2004).
92. Champion L, Stern M, Israel-Biet D et al. Brief communication: sirolimus-associated pneumonitis: 24 cases in renal transplant recipients. Ann. Intern. Med. 144(7), 505-509 (2006).
93. Morelon E, Stern M, Israel-Biet D et al. Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients. Transplantation 72(5), 787-790 (2001).
94. Rehm B, Keller F, Mayer J, Stracke S. Resolution of sirolimus-induced pneumonitis after conversion to everolimus. Transplant. Proc. 38(3), 711-713 (2006).
95. Weiner SM, Sellin L, Vonend O et al. Pneumonitis associated with sirolimus: clinical characteristics, risk factors and outcome - a single-centre experience and review of the literature. Nephrol. Dial. Transplant. 22(12), 3631-3637 (2007).
96. Geissler EK, Schlitt HK. The potential benefits of rapamycin on renal function, tolerance, fibrosis, and malignancy following transplantation. Kidney Int. 78(11), 1075-1079 (2010).